RELATIVITY-123: A phase 3, randomized, open-label study of nivolumab (NIVO) + relatlimab (RELA) fixed-dose combination (FDC) versus regorafenib or trifluridine + tipiracil (TAS-102) in later-line ...
Figure 1: Sequences of mutations found in selected RM patients. To rule out the presence of non-pathogenic sequence variants, all described mutations, including the 'double mutant' sites, ...
Following more than two decades at Hopeless Records, the company’s executive vice president Ian Harrison recently succeeded Dr Richard James Burgess as CEO of A2IM, the US independent music coalition ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results